ERBB2 and gastroesophageal junction adenocarcinoma: This trial showed statistically significant and clinically meaningful improvement in OS, PFS, and ORR in all patients with unresectable or metastatic HER2+ gastric/GEJ adenocarcinoma, especially in patients with dual HER2 positivity and PD-L1 CPS ≥1 [14].